-
公开(公告)号：US20240102999A1
公开(公告)日：2024-03-28
申请号：US18523859
申请日：2023-11-29
Applicant: Hoffmann-La Roche Inc.
Inventor： Uwe DAHL , Gregor JORDAN , Roland STAACK
IPC: G01N33/557 , G01N33/15
CPC classification number: G01N33/557 , G01N33/15
Abstract: Herein is reported a method for the determination of the binding affinity of a binder and its ligand comprising the step of determining based on the result of an immunoassay the fraction of free binder in a sample comprising binder, ligand and binder-ligand-complexes for at least two different binder:ligand ratios in the sample, and if the determined fraction of free binder is not comparable for all used binder:ligand ratios then the binder:ligand ratio in the sample is lowered and the sample is re-analyzed by the same immunoassay, and calculating based on the fraction of free binder in the previous step the binding affinity for the binder to its ligand.
-
公开(公告)号：US20230227584A1
公开(公告)日：2023-07-20
申请号：US17937440
申请日：2022-09-30
Applicant: Hoffmann-La Roche Inc.
Inventor： Maria AMANN , Ali BRANSI , Peter BRUENKER , Janine FAIGLE , Sabine IMHOF-JUNG , Roland STAACK , Joerg ZIELONKA
CPC classification number: C07K16/468 , C12N15/63 , C07K2317/31 , C07K2317/35 , C07K2317/55 , C07K2317/522
Abstract: The present invention relates to bispecific antibodies comprising a modified C-terminal crossfab fragment that have reduced or no reactivity against preexisting antidrug antibodies.
-
公开(公告)号：US20220025046A1
公开(公告)日：2022-01-27
申请号：US17218948
申请日：2021-03-31
Applicant: Hoffmann-La Roche Inc.
Inventor： Maria AMANN , Juergen Peter BACHL , Alexander BUJOTZEK , Carina CANTRILL , Harald DUERR , Janine FAIGLE , Sabine IMHOF-JUNG , Christian KLEIN , Thomas KRAFT , Estelle MARRER-BERGER , Ekkehard MOESSNER , Laurene POUSSE , Petra RUEGER , Johannes SAM , Roland STAACK , Dietrich TUERCK , Pablo UMANA , Joerg ZIELONKA
Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
-
Patent Agency Ranking
公开(公告)号：US20240117049A1
公开(公告)日：2024-04-11
申请号：US18457729
申请日：2023-08-29
Applicant: Hoffmann-La Roche Inc.
Inventor： Maria AMANN , Juergen Peter BACHL , Alexander BUJOTZEK , Carina CANTRILL , Harald DUERR , Janine FAIGLE , Sabine IMHOF-JUNG , Christian KLEIN , Thomas KRAFT , Estelle MARRER-BERGER , Ekkehard MOESSNER , Laurene POUSSE , Petra RUEGER , Johannes SAM , Roland STAACK , Dietrich TUERCK , Pablo UMANA , Joerg ZIELONKA
CPC classification number: C07K16/2809 , A61K45/06 , A61P35/00 , C07K16/2878 , C07K16/30 , C07K16/468 , C12N15/63 , A61K2039/505
Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
-
公开(公告)号：US20230063268A1
公开(公告)日：2023-03-02
申请号：US17982361
申请日：2022-11-07
Applicant: Hoffmann-La Roche Inc.
Inventor： Gregor JORDAN , Roland STAACK
IPC: G01N33/68 , G01N33/536
Abstract: Herein is reported a method for the determination of the presence of anti-drug antibodies in a sample comprising the steps of incubating the sample with MgCl2 at a final concentration in the range of 1 N to 12 N; adding a tracer antibody and incubating the sample thereafter; incubating the isolated tracer antibody-anti-drug antibody-complexes with a detection antibody conjugated to a detectable label and determining the presence of anti-drug antibodies if a signal above a threshold level is obtained.
-
公开(公告)号：US20240002483A1
公开(公告)日：2024-01-04
申请号：US18037071
申请日：2021-11-04
Applicant: Hoffmann-La Roche Inc.
Inventor： Klaus JOERIS , Neslihan OEZDEN , Wolfgang RICHTER , Britta SCHMIDT , Carsten HOFMANN , Wilma LAU , Roland STAACK
CPC classification number: C07K16/18 , C07K16/2881 , C07K2317/41 , C07K2317/55 , C07K2317/31 , A61K2039/505
Abstract: The present invention relates to glycosylation patterns at the Fab portion of a monoclonal antibody and methods for the regulation during culture of a microorganism expressing a monoclonal antibody with regulated content of high mannose Fab glycoforms.
-
公开(公告)号：US20220357340A1
公开(公告)日：2022-11-10
申请号：US17806869
申请日：2022-06-14
Applicant: Hoffmann-La Roche Inc.
Inventor： Kevin BRADY , Gregor JORDAN , Sylvia ROTTACH , Martin SCHAEFER , Roland STAACK , Kay-Gunnar STUBENRAUCH
IPC: G01N33/68 , G01N33/543
Abstract: Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced, wherein the concentration of the therapeutic antibody in the tissue of the experimental animal is calculated with the following formula: C tmAb , tissue = C t m A b , tissue , det . C t i s sue , sample - C r e f m A b , tissue , det . C t i s sue , sample C r e f m A b , plasma . det . * C t m A b , plasma , det . wherein CtmAb,tissue,det.=obtained by determining the concentration of the therapeutic antibody in the tissue sample of the experimental animal, CtmAb,plasma,det.=obtained by determining the concentration of the therapeutic antibody in a blood sample of the experimental animal directly prior to taking the tissue sample, CrefmAb,tissue,det.=obtained by determining the concentration of the inert reference antibody in the tissue sample of the experimental animal, CrefmAb,plasma,det.=obtained by determining the concentration of an inert reference antibody in the blood sample of the experimental animal directly prior to taking the tissue sample, Ctissue,sampie=obtained by determining the tissue concentration in the tissue sample, whereby the inert reference antibody does not penetrate into said tissue, whereby the inert reference antibody is administered 2 to 10 minutes prior to obtaining the tissue and blood sample.
-
公开(公告)号：US20190011440A1
公开(公告)日：2019-01-10
申请号：US16009369
申请日：2018-06-15
Applicant: Hoffmann-La Roche Inc.
Inventor： Gregor JORDAN , Roland STAACK
IPC: G01N33/543 , G01N33/536 , G01N33/58
CPC classification number: G01N33/54306 , G01N33/536 , G01N33/58 , G01N33/6854 , G01N33/94
Abstract: Herein is reported a method for determining in a sample the (total, i.e. binding competent) amount of a ligand of a ligand-binding protein (therapeutic) comprising the following steps in the following order: subjecting the sample to an acid treatment, forming in solution a non-covalent complex comprising i) an anti-ligand antibody, ii) the ligand, and iii) labelled ligand-binding protein, by adding anti-ligand antibody and labelled ligand-binding protein to the sample, and determining the amount of the complex and thereby determining the amount of the ligand of the ligand-binding protein.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.029 seconds)
